UPDATE: Goldman Sachs Downgrades Seres Therapeutics (MCRB) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Wall St set for higher open as chip stocks bounce back after selloff
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- European stocks edge higher as dollar eases, oil prices fall
- Dollar rally stalls after rare FX warning from finance chiefs
- Oil extends losses on easing Middle East tension, demand concerns
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Tesla, Blackstone, Las Vegas Sands fall premarket; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
July 22, 2021 7:33 AM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative... More
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
July 22, 2021 7:00 AM EDTPrimary endpoint of clinical remission compared to placebo was not achieved
Both dosing regimens of SER-287 were generally well tolerated
Open label and maintenance portions of the SER-287 study will be closed
Microbiome endpoints and analyses expected in the second half of 2021
Company to host a conference call at 8:30 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS... More
